Evidence map›Paper›PMID 37034167›Full record

ArticleFrontiers in neuroscience2023

Diabetic rats with high levels of endogenous dopamine do not show retinal vascular pathology.

Rachael S Allen, Cara T Khayat, Andrew J Feola, Alice S Win, Allison R Grubman, Kyle C Chesler, Li He, Jendayi A Dixon, Timothy S Kern, P Michael Iuvone and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Dopamine: A New Player in the Pathogenesis of Diabetic Retinopathy?International journal of molecular sciences · 2024
    Review
  6. Review
  7. Article
  8. Review
  9. Development of an Automated Electroretinography Analysis Approach.Translational vision science & technology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Rachael S AllenAtlanta VA Center for Visual and Neurocognitive Rehabilitation, Atlanta VA Healthcare System, Decatur, GA, United States.
Cara T KhayatAtlanta VA Center for Visual and Neurocognitive Rehabilitation, Atlanta VA Healthcare System, Decatur, GA, United States.
Andrew J FeolaAtlanta VA Center for Visual and Neurocognitive Rehabilitation, Atlanta VA Healthcare System, Decatur, GA, United States.
Alice S WinAtlanta VA Center for Visual and Neurocognitive Rehabilitation, Atlanta VA Healthcare System, Decatur, GA, United States.
Allison R GrubmanAtlanta VA Center for Visual and Neurocognitive Rehabilitation, Atlanta VA Healthcare System, Decatur, GA, United States.
Kyle C CheslerAtlanta VA Center for Visual and Neurocognitive Rehabilitation, Atlanta VA Healthcare System, Decatur, GA, United States.
Li HeDepartment of Ophthalmology, Emory University, Atlanta, GA, United States.
Jendayi A DixonDepartment of Ophthalmology, Emory University, Atlanta, GA, United States.
Timothy S KernDepartment of Pharmacology, Case Western Reserve University, Cleveland, OH, United States.
P Michael IuvoneDepartment of Ophthalmology, Emory University, Atlanta, GA, United States.
Peter M ThuleSection Endocrinology and Metabolism, Atlanta VA Medical Center, Emory University School of Medicine, Decatur, GA, United States.
Machelle T PardueAtlanta VA Center for Visual and Neurocognitive Rehabilitation, Atlanta VA Healthcare System, Decatur, GA, United States.
Atlanta VA Health Care System · USEmory University · USGeorgia Institute of Technology · USAtlanta VA Medical Center · USUniversity of California, Irvine · US

Funding

VIsion Science Training in AtlantaT32EY007092 · NEI · EMORY UNIVERSITY · PI Machelle T. Pardue · 1985 to 2026
$4.6M
Dopamine treatments for diabetic retinopathyI01RX002615 · VA · VETERANS HEALTH ADMINISTRATION · PI PARDUE, MACHELLE T. · 2018 to 2021
–
RR&D Research Career Scientist Award ApplicationIK6RX003134 · VA · VETERANS HEALTH ADMINISTRATION · PI PARDUE, MACHELLE T. · 2019 to 2025
–
NEI NIH HHS T32 EY007092RRD VA I01 RX002615RRD VA IK2 RX002342RRD VA IK2 RX002928RRD VA IK6 RX003134
6 · The paper itself

Abstract

Purpose: Limited research exists on the time course of long-term retinal and cerebral deficits in diabetic rodents. Previously, we examined short term (4-8 weeks) deficits in the Goto-Kakizaki (GK) rat model of Type II diabetes. Here, we investigated the long-term (1-8 months) temporal appearance of functional deficits (retinal, cognitive, and motor), retinal vascular pathology, and retinal dopamine levels in the GK rat. Methods: In GK rats and Wistar controls, retinal neuronal function (electroretinogram), cognitive function (Y-maze), and motor function (rotarod) were measured at 1, 2, 4, 6, and 8 months of age. In addition, we evaluated retinal vascular function (functional hyperemia) and glucose and insulin tolerance. Retinas from rats euthanized at ≥8 months were assessed for vascular pathology. Dopamine and DOPAC levels were measured Results: Goto-Kakizaki rats exhibited significant glucose intolerance beginning at 4 weeks and worsening over time ( Conclusion: As shown previously, retinal deficits were detectable prior to cognitive deficits in GK rats. While retinal neuronal function was compromised, retinal vascular pathology was not observed, even at 12+ months. High endogenous levels of dopamine in the GK rat may be acting as an anti-angiogenic and providing protection against vascular pathology.

Indexed as

cognitivediabetesdiabetic retinopathydopamineelectroretinogramGoto-Kakizakivascular

Identifiers

PMID37034167
PMCPMC10073440
OpenAlexW4353083207

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.